Access Programs for ABL001, Asciminib

Sponsor: Novartis Pharmaceuticals

Expanded Access
Sponsor score: 60
Inactive

ClinicalTrials ID:NCT04360005

Provider View

This program provides access to the drug ABL001, also known as asciminib, for patients with serious conditions who cannot find other suitable treatments and are not eligible for clinical trials.

Patient Parameters

Program Overview

The Managed Access Programs (MAPs) for ABL001, asciminib, are designed to provide this medication to patients with serious or life-threatening conditions when no other satisfactory treatment options are available. These programs are intended for patients who cannot participate in clinical trials and may benefit from the drug despite potential risks.

Eligibility Criteria

Inclusion Criteria

  • A licensed doctor has independently requested the drug for the patient.
  • The patient has a serious or life-threatening condition with no other suitable treatment options.
  • The patient cannot join or continue in a clinical trial.
  • The potential benefits of using the drug outweigh the risks, considering the patient's condition.
  • The patient meets any additional medical criteria set by experts or local health authorities.
  • Providing the drug will not disrupt any ongoing or planned clinical trials by Novartis.
  • The program is allowed under local laws and regulations.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.